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The role of tuberous sclerosis complex (TSC) in the pathogenesis of pancreatic cancers remains largely unknown.
The present study shows that neurogenin 3 directed Cre deletion of Tsc1 gene induces the development of
pancreatic acinar carcinoma. By cross-breeding the Neurog3-cre mice with Tsc1loxp/loxp mice, we generated the
Neurog3-Tsc1−/− transgenic mice in which Tsc1 gene is deleted and mTOR signaling activated in the pancreatic
progenitor cells. All Neurog3-Tsc1−/− mice developed notable adenocarcinoma-like lesions in pancreas starting
from the age of 100 days old. The tumor lesions are composed of cells with morphological and molecular
resemblance to acinar cells. Metastasis of neoplasm to liver and lung was detected in 5% of animals. Inhibition of
mTOR signaling by rapamycin significantly attenuated the growth of the neoplasm. Relapse of the neoplasm
occurred within 14 days upon cessation of rapamycin treatment. Our studies indicate that activation of mTOR
signaling in the pancreatic progenitor cells may trigger the development of acinar carcinoma. Thus, mTOR may
serve as a potential target for treatment of pancreatic acinar carcinoma.
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Pancreatic cancer is one of the most leading causes of cancer deaths in
the United States and many other developed countries [1]. Despite
the comprehensive treatment options including surgery resection,
radiotherapy, and chemotherapy, the five-year survival rate remains
steady at 3% to 5% in the past three decades [2]. The pancreatic
cancer is usually silent at the early stage, and most patients have
already reached the advanced stage at the time of diagnosis [3]. Most
of the pancreatic cancers are ductal adenocarcinoma (PDA). Acinar
cell carcinoma (ACC) is rare, accounting for 1% of all pancreatic
cancer diagnoses [4]. ACC differs significantly from the more
common PDA. The histologic and immunohistochemical (IHC)
findings are distinctive and the molecular alterations share little
common with PDA [5]. ACC lacks mutations in genes associated
with PDA, such as V-Ki-ras2 Kirsten rat sarcoma viral oncogene
homolog (KRAS), tumor protein 53 (TP53), deleted in pancreatic
cancer 4 (DPC4), and p16 [6]. Instead, ACC may have abnormalities
in the adenomatosis polyposis coli gene and β-catenin [5].
Contemporary treatment of pancreatic cancer is often ineffective
because current understanding on the risk factors and etiology of
pancreatic cancer from environmental and genetic perspective isincomplete. Using the genetically engineered mouse models to
recapitulate human pancreatic neoplasia, scientists have gradually
uncovered the core signaling pathways and regulatory processes
critical for the development of pancreatic cancers [7].
One of the important signaling pathways implicated in the
development of pancreatic cancers is the tuberous sclerosis complex
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member of the phakomatoses and tumor suppressor genes, TSC is
associated with benign tumors, most notably in the central nervous
system. In addition, functional links between the TSC genes and
other tumor suppressors responsible for Cowden's disease (PTEN),
Peutz-Jeghers syndrome (LKB1), and familial polyposis (APC)
suggest that TSC may contribute to the development of pancreatic
cancers [9]. As the inhibitors of the mTOR signaling pathway, TSC1
and TSC2 form as the heterodimer to inhibit mTOR signaling and
subsequently attenuate cell growth, proliferation, division, and
survival [10]. Expression analyses have indicated that the expression
of genes in the mTOR pathway is altered frequently in pancreatic
neuroendocrine tumors (15%), but not in pancreatic ductal
adenocarcinomas (0.80%) [11]. However, Pten is lost in a large
number of PDAC tumors and mTOR might play a role in PDAC
stem cells [12,13]. Animal studies have demonstrated that deletion of
ribosomal protein (rp) S6 renders the mice resistant to pancreatic
cancer precursor lesions induced by either 7,12-Dimethylbenz(a)
anthracene (DMBA) or mutation of Kras [14]. Furthermore,
inhibition of mTOR signaling attenuates the growth of pancreatic
cancer cell lines both in vitro and in vivo [15–18]. Everolimus, a
selective inhibitor of mTORC1, has been shown to increase
progression-free survival in a subset of pancreatic neuroendocrine
tumors patients with advanced disease [19]. All these data suggest that
the TSC-mTOR signaling pathway is associated with the develop-
ment of pancreatic cancers. Nonetheless, two important questions
remain to be unraveled. Does activation of mTOR signaling lead to
the development of pancreatic cancer? Which type of pancreatic
cancer, ie the neuroendocrine, the ductal adenocarcinoma, or acinar
cell carcinoma is caused by activation of mTOR signaling. To address
these questions, we generated a new genetically engineered mouse
model Neurog3-Tsc1−/− mice by cross-breeding the Neurog3-cre mice
with Tsc1loxp/loxp mice. The functional domain of Tsc1 gene was
deleted and mTOR signaling thus activated in pancreatic progenitor
cells expressing neurogenin 3 in the transgenic mice. Adenocarcinoma-
like lesions were observed starting from 100 days in Neurog3-Tsc1−/−
mice. The tumor lesions are malignant epithelial neoplasm composed of
cells with morphological resemblance to acinar cells and with evidence
of α-amylase production, a typical pancreatic exocrine enzyme.
Metastasis to liver and lung was observed in 5% of animals. The
neoplasm was significantly attenuated by rapamycin, a selective
inhibitor of mTOR signaling. Relapse of the neoplasm occurred within
14 days upon cessation of the rapamycin treatment. All these data
suggest that activation of mTOR signaling in the pancreatic progenitor
cells may trigger the development of acinar carcinoma.
Materials and Methods
Materials
Rabbit anti-S6, rabbit anti-phospho-S6 (ser235, 236), rabbit anti-
4EBP-1, rabbit anti-phospho-4EBP-1 (Thr37, 46), rabbit anti-β-
Catenin (species cross-reactivity: human, mouse, and rat) and mouse
anti-proliferating cell nuclear antigen (PCNA) were from Cell
Signaling Technology (Beverly, MA). Rabbit anti-α-Amylase was
from Sigma Chemical Co. (St. Louis, MO). Mouse anti-CA19-9 was
from Origene (Beijing, China). Goat anti-insulin A (C-12) (species
cross-reactivity: human, mouse, and rat), Goat anti-glucagon (N-17)
(species cross-reactivity: human, mouse, and rat), rabbit anti-
somatostatin (FL-116) (species cross-reactivity: human, mouse, andrat), goat anti-rabbit fluoresceinisothiocyanate-conjugated IgG,
donkey anti-goat fluoresceinisothiocyanate- conjugated IgG, donkey
anti-goat Texas Red-conjugated IgG, goat anti-mouse Texas Red-
conjugated IgG, and chicken anti-rabbit fluoresceinisothiocyanate-
conjugated IgG and rapamycin were purchased from Santa Cruz
Biotechnology Inc. (Santa Cruz, CA). Dimethylsulfoxide was from
Sigma Chemical Co. (St. Louis, MO). Aprotinin was purchased from
Amersham Biosciences (Pittsburgh, PA). IRDye-conjugated affinity
purified anti-rabbit, anti-mouse IgGs were purchased from Rockland
(Gilbertsville, PA).
Animals and Animal Care
Neuroge3-Cre mice that express the Cre recombinase gene under
the control of the Neurogenin3 gene promoter, as well as Tsc1loxP/loxP
mice, in which exons 17 and 18 of the Tsc1 gene are flanked by loxP
sites by homologous recombination, were purchased from the Jackson
Laboratory (Bar Harbor, ME). For Tsc1loxp/loxp mice, a targeting
vector containing a loxP-flanked neomycin resistance-thymidine
kinase gene cassette preceding exon 17 and a third loxP site
downstream of exon 18 was electroporated into 129S4/SvJae derived
J1 embryonic stem (ES) cells. Correctly targeted ES cells were injected
into C57BL/6 J blastocysts. Chimeric mice were backcrossed for
germ-line transmission to 129/SvJae mice. For Neurogenin3-cre
mice, a bacterial artificial chromosome (BAC) encoding the mouse
neurogenin 3 sequence was modified by the insertion of a Cre
recombinase gene, preceded by nuclear localization sequence, into
exon 1 of the neurogenin 3 gene at the initiator methionine. The
BAC was injected into FVB/N embryos which were next implanted
into pseudopregnant CD1 females. Founder line C1 was obtained and
backcrossed to CD1 mice for 7 generations after which mice were
intercrossed. The Neurog3-Tsc1−/− mice were generated by breeding
Tsc1loxP/loxP mice with Neurog3-Cre mice. Control experiments were
performed using littermate Tsc1loxP/loxP animals. Deletion of the Tsc1
gene was validated by the absence of its mRNA and protein, and the
increased phosphorylation of 4EBP-1 and S6, its downstream signaling
molecules, in pancreas tissues.Mice were housed on a 12 h–12 h light–
dark cycle. Normal chow and water were available ad libitum.
Genotyping
For genotyping, genomic DNA was extracted from tail cuttings.
Polymerase chain reactions were carried out for each animal to test for the
presence of the TSC1 and/or the deletion of its exons 17 and 18 using
LoxP primers, and Cre constructs using cre-specific primers, respectively.Immunostaining
Mice were deeply anesthetized using sodium pentobarbital
(40 mg/kg, ip), perfused transcardially with 20 ml 0.1 M PBS
(pH 7.4), followed by 20 ml 4% paraformaldehyde in PBS. The
whole pancreas was quickly removed and fixed in 4% paraformal-
dehyde, followed by dehydrated, embedded in wax, and sectioned at
6 μm. Tissue sections were de-paraffinized and hydrated by graded
washes with xylene and ethanol. Antigen retrieval was accomplished
by boiling in 10 mM sodium citrate acid buffer (pH 6.0) for
15 minutes. Endogenous peroxidase activity was blocked by
incubation of slides in 3% H2O2 for 10 minutes. Nonspecific
binding was blocked with 1% bovine serum albumin. Sections were
then incubated with primary antibodies overnight at 4°C. For
immunohistochemistry, secondary antibody staining was performed
with a poly-HRP detection system for rabbit or mouse primary
Figure 1.Deletion of TSC1 and activation ofmTOR signaling in the pancreas ofNeurog3-TSC1−/− transgenicmice. TheNeurog3-Tsc1−/−
mice were generated by breeding Tsc1loxP/loxP mice with Neurog3-Cremice. TSC1, phospho-S6 (pS6), and phospho-4EBP-1 in pancreatic
tissue with tumor nodules were examined by Western blotting using specific antibodies. S6, 4EBP-1, and β-actin were used as loading
controls. Shown are representative results from 6 experiments. Signal intensity of TSC1, pS6, p4EBP-1, and PCNA were analyzed and
expressed as mean ± SEM. n = 6. *P b .05 versus wild-type mice.
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1 hour at room temperature. Immunoreactivity was detected using
diaminobenzidine substrate (peroxide substrate kit, SK-4100; Vector
Laboratories) for 2–5 minutes. Slides were then counterstained with
Mayer’s hematoxylin before dehydration and mounting. For
immunofluorescence, secondary antibodies used included chicken
anti-rabbit fluoresceinisothiocyanate-conjugated IgG (1:100), goat
anti-mouse Texas Red-conjugated IgG (1:100 dilution), goat anti-
rabbit fluoresceinisothiocyanate-conjugated IgG (1:100 dilution),
donkey anti-goat fluoresceinisothiocyanate-conjugated IgG (1:100
dilution) and donkey anti-goat Texas Red-conjugated IgG (1:100
dilution). Pancreatic tissues were incubated with secondary antibody for
1 hour at room temperature. Fluorescent signals were observed and
photomicrographs taken under a confocal laser scanning microscope
(Leica, Germany). Controls included substituting primary antibodies
with relevant IgGs.
Western Blot Analysis
Tissues extracts were immunoblotted with TSC1 (1:600 dilution),
S6 (1:1000 dilution), pS6 (1:1000 dilution), β-actin(1:1000 dilution),
4EBP-1 (1:1000 dilution), p4EBP-1 (1:1000 dilution), β-Catenin
(1:1000 dilution) as described previously [20,21]. Briefly, pancreatic
tissues were isolated and homogenized in lysis buffer. Proteins were
subjected to SDS-PAGE with a 10% running gel, then transferred to a
polyvinylidene fluoride membrane. Membranes were incubated for
1 hour at room temperature with 5% fat-free milk in Tris bufferedsaline containing Tween 20, followed by incubation overnight at 4°C
with primary antibodies. Specific reaction was detected using IRDye-
conjugated second antibody and visualized using the Odyssey infrared
imaging system (LI-COR Biosciences, Lincoln, NE).
Rapamycin Treatment
Rapamycin (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) was
initially dissolved in 100% DMSO, stored at −20 °C, and further
diluted in DMSO immediately before use. Animals bearing the
neoplasm as confirmed by ultrasound imaging were treated daily by
intraperitoneal injection with rapamycin at the dose of 1 mg/kg for
consecutive 28 days. The neoplasmwasmonitored by ultrasound at the
times indicated before, during, and after treatment with rapamycin.
Ultrasound Imaging
Image of pancreatic neoplasm was examined by an experienced
hepatic-biliary-pancreatic radiologist using a Philips iU22 machine
(Philips Ultrasound, USA) according to the manufacturer’s guidelines.
Ultrasound images of the lesions were recorded using a high-frequency
probe (5 to 12 MHz) prior and subsequent to rapamycin treatment at
the times indicated.
Statistical Analysis
Data were expressed as mean ± SEM and analyzed by repeated-
measures analysis of variance, one-way ANOVA, Student–Newman–
Keuls test (comparisons between multiple groups), unpaired
Student’s t test (between two groups) and non-parametric test as
Figure 2. Pancreatic neoplasms inNeurog3-Tsc1−/−mice. (A) Abdominal swelling and palpable mass were observed in Neurog3-Tsc1−/
−mice (TN), but not in wild-type littermates (WT). (B) Pancreatic tumor incidence and survival rate (C) for Neurog3-Tsc1−/− (n = 25) and
wildtypemice (n = 15) analyzed by Kaplan-Meier. (D) Gross photograph of multi-nodular pancreatic tumors. T, L, and S indicate tumor,
liver, and spleen, respectively. (E) Tumor size. Tumor size was measured at the week of 45.
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Inc., La Jolla, CA). A value of P b .05 denotes statistical significance.
Study Approval
The animals used in this study were reviewed and approved by the
Animal Care and Use Committee of Peking University in accordance
with the Guide for the Care and Use of Laboratory Animals published
by the US National Institutes of Health (NIH publication no. 85–23,
revised 1996).
Results
Generation of Neurog3-Tsc1−/− Mouse Strain and Validation
of mTOR Activation in Pancreas
By cross-breeding the Neurog3-Cre mice with Tsc1loxp-loxp mice,
we have generated a mouse strain Neurog3-Tsc1−/−. Analysis of
pancreatic TSC1 and its related mTOR signaling molecules validated
the deletion of Tsc1 gene in the pancreas. As shown in Figure 1,
TSC1 expression was detected at a relative high level in the pancreas
in the wild-type littermate control (WT), whereas Neurog3-Tsc1−/−
(TN) mice demonstrated a significant reduction of TSC1 immuno-
reactivity. Since TSC1 has been recognized as the negative upstream
regulator of mTOR signaling in many cell types, we next examinedthe mTOR activity in the pancreas. Phosphorylation of S6 ribosomal
protein (pS6) and 4E binding protein 1 (p4EBP1), the downstream
targets of mTOR [10], and proliferating cell nuclear antigen (PCNA)
was significantly increased in pancreas of the Neurog3-Tsc1−/− (TN)
mice relative to the control littermates (WT). These data indicate that
deletion of TSC1 results in activation of mTOR signaling in the
pancreas of Neurog3-Tsc1−/−(TN) mice. Thus, we have successfully
generated a mouse strain with pancreatic deletion of TSC1 and
subsequent activation of mTOR signaling.
Development of Pancreatic Neoplasm in Neurog3-Tsc1−/− Mice
As a critical molecule controlling the cell proliferation, mTOR
influences tumor development and growth in many tissues [22–24].
We thus explored the occurrence of pancreatic neoplasm in the
Neurog3-Tsc1−/− mice. As shown in Figure 2A, abdominal swelling
appeared and palpable mass was found inNeurog3-Tsc1−/−mice starting
from 100 days old. By the age of 300 days old, all Neurog3-Tsc1−/−
animals (n = 25) developed palpable mass in the pancreas (Figure 2B).
Analysis of survival rate demonstrated that allNeurog3-Tsc1−/−mice died
by the age of 13 months, whereas 100% of wild-type littermates survived
at least 16 months (Figure 2C). Autopsies revealed multinodular
pancreatic tumors ranging from 3 to 25 mm in diameter of individual
Figure 3. Histology of the pancreas from WT and TN mice. (A) Cross section of normal pancreas (left) and pancreatic neoplasm (right)
from representative of 8-month-old wild-type littermates (WT) and Neurog3-Tsc1−/− (TN) mice respectively. (B) Micrograph of normal
pancreas (upper) and neoplasm (lower). Hematoxylin and eosin (H&E) staining showed the distinct epithelial neoplasm with cellular and
structure resemblance of pancreatic acini.
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and E). No tumor was observed in wild-type littermates up to the age of
16 months.
Recapitulation of the Pathologic Features of Human Pancreatic
Acinar Adenocarcinoma in Neurog3-Tsc1−/− Mice
Both morphological and immunoreactivity analysis of the
pancreatic tumor in Neurog3-Tsc1−/− mice revealed the hallmarks
of human pancreatic acinar adenocarcinomas (Figure 3). Tumor
lesions are composed of well circumscribed nodules with necrotic foci
(Figure 3A). Microscopic examination revealed distinct epithelial
neoplasm with evidence of low-grade malignancy. Tumors are highly
cellular with gross lobules separated by scant fibrous stroma. Tumor
cells are arranged predominantly in acinar patternmixedwith trabecular
or solid structure (Figure 3B). Nuclei are somewhat irregular in size and
polarized in acinar formations (Figure 3B). Nuclear atypia and mitoses
are rare. Hemorrhage and necrosis are common.
The abundant eosinophilic granular apical cytoplasm in the tumor
cells suggests the morphological resemblance to acinar cells. We thus
examined the presence of zymogen granules by immunostaining to
detect the expression of α-amylase, a pancreatic exocrine enzyme. As
shown in Figure 4, moderate α-amylase immunoreactivity wasdetected in tumor cells of Neurog3-Tsc1−/− mice, while surrounding
normal acinar cells demonstrated a strong signal (Figure 4A, red).
Unlike normal pancreas in Neurog3-Tsc1−/− transgenic mice and
wild-type littermates, the acinar lesions demonstrated negative
immunoreactivity for carbohydrate antigen 19–9 (CA19-9)
(Figure 4A, green), a selective marker for pancreatic duct epithelial
cells. Furthermore, immunoreactivity for chromogranin A, an
endocrine cell marker, was not detected in the tumor cells, whereas
surrounding islet cells showed strong signal (Figure 4A). Significant
increases in levels of amylase mRNA (Figure 4C) and protein
(Figure 4B) were detected in the pancreatic tumor ofNeurog3-Tsc1−/−
mice relative to wild-type littermates.
Metastasis of the Pancreatic Neoplasm in Neurog3-Tsc1−/−Mice
Given the invasive behavior of the pancreatic acinar adenocar-
cinomas, we conducted a histologic survey of organs for evidence of
metastasis. This survey revealed metastasis of the pancreatic
neoplasm to the liver (Figure 5A) and the lungs (Figure 5B) in 2
(5%) of 40 Neuroge3-Tsc1−/− mice. The metastasis lesions in liver
was histologically confirmed to be of pancreatic origin by the
staining of α-amylase (Figure 5C), although lymph nodes metas-
tasis was not detected.
Figure 4. Histological and immunoreactivity analysis. (A) Shown are the representative of normal pancreas and neoplasm from 8-month-
old wild-type (WT) (upper panel) and Neurog3-Tsc1−/− (TN) mice (lower panel) respectively. (1) H&E staining shows solid, well-
demarcated pancreatic adenocarcinoma in TNmice. (2) Chromogranin A immunoreactivity (CgA, arrow) was observed in pancreatic islets
but not the neoplasm. (3) Amylase immunoreactivity was strong in pancreatic acinar cells, while neoplasm demonstrated modest
staining. (4) Ductal cells stained positive for CA19-9, a specific marker for ductal cells, while neoplasm had no staining. (B) Amylase in
pancreas with tumor nodules was examined by western blot. Shown are representative results from 6 experiments. (C) Expression of
Amylase mRNA in pancreas with tumor nodules was examined by qPCR. n = 5. *P b .05 versus wild type mice.
Figure 5.Metastasis of the pancreatic neoplasm in Neurog3-TSC1−/−mice. (A) Hepatic metastases (arrows). (B) Pulmonary metastases
(arrows). (C) The hepatic lesion was demonstrated to be of pancreatic origin by histological and immunoreactivity examination. Cells of
the metastatic neoplasm resembled the original pancreatic lesion and were positive for α-amylase.
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Figure 6.Ultrasound imaging of the pancreatic lesions inNeurog3-TSC1−/−mice. (A) Representative ultrasound images of the pancreatic
neoplasms before, during, and after treatment with rapamycin. Mice were treated intraperitoneally with 1 mg/kg rapamycin for 28
consecutive days. The pancreatic lesions were examined on day 0, 14, 28 during treatment, and 14 days after stoppage of rapamycin
treatment. (B) The diameter of pancreatic lesions was measured and expressed as mean ± SEM in cm. Asterisk denotes P b .01. n = 5.
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Neuroge3-Tsc1−/− mice
To further demonstrate that Tsc1-mTOR signaling is critical for the
development of pancreatic acinar adenocarcinomas inNeuroge3-Tsc1−/−
mice, we used rapamycin to block themTOR signaling and evaluated its
effect on the tumor growth. The neoplasm was monitored by
transabdominal ultrasonography which was chosen because of its non-
invasive, non-radioactive nature and the comparative difficulty in
imaging the mouse pancreas with other technologies [25]. Prior to
rapamycin treatment (defined as day 0), the existence of pancreatic
neoplasm was confirmed and recorded by B-mode ultrasonic
examination. Abdominal mass with well-defined heterogeneous internal
echoes mass was depicted by B-mode ultrasonic examination. Signature
of lower or even non-echoes was also detected, suggesting the presence of
different degrees of necrosis in tumor lesions. As shown in Figure 6, daily
intraperitoneal injection of rapamycin at a dose of 1 mg/kg significantly
reduced the pancreatic neoplasm in Neuroge3-Tsc1−/− mice. The
diameter of lesions was significantly reduced from 0.89 ±0.04 cm at
day 0 to 0.58 ± 0.02 cm and 0.40 ± 0.03 cm at day 14 and 28
respectively (P b 0.05, n = 6). Interestingly, relapse of tumors occurred
upon cessation of rapamycin treatment with tumor size returned to the
level prior to treatment (0.83 ± 0.06 cm versus 0.89 ±0.04, P b .05).
Discussion
The present study demonstrates that activation of mTOR signaling
by deletion of Tsc1 gene in cells expressing neurogenin 3 results in the
development of pancreatic acinar carcinoma. This general conclusionis supported by the following distinct observations: (1) level of TSC1
is significantly reduced, whereas mTOR activity increased in the
pancreas of Neuroge3-Tsc1−/− mice relative to wild-type littermates;
(2) hundred percent of Neuroge3-Tsc1−/− mice develops pancreatic
neoplasm by the age of 300 days; (3) no Neuroge3-Tsc1−/− mouse
survives over 13 months; (4) the pancreatic neoplasm resembles low
grade acinar adenocarcinoma with tumor cells arranged in acinar
pattern and evidence of pancreatic exocrine enzyme production;
(5) metastasis to liver and lungs occurs in 5% of Neuroge3-Tsc1−/−
mice; (6) inhibition of mTOR signaling by rapamycin attenuates the
growth of the pancreatic neoplasm.
Genetically engineered mouse models are invaluable for the
understanding of the pathobiology of pancreatic neoplasia, and thus
provide an indispensible tool for the development of novel
therapeutic drugs for this deadly lesion. Most of the mouse transgenic
models of pancreatic neoplasms were developed using the elastase 1
(EL-1) promoter, an enzyme with the highest specificity for the
pancreas [26–28]. Dependent on the oncogenes used, three general
types of exocrine pancreatic neoplasms have been reported: pure acinar
cell neoplasms, dominantly acinar cell neoplasms with conspicuous
ductal metaplasia, and duct-like neoplasms. Since elastase I is solely
expressed in the differentiated acinar cells, the presence of duct cell
neoplasms in the transgenic mice such as EL-1-myc, EL-1-Kras, and
EL-1-Hras suggests the background changes of acinar to ductal cell
metaplasia. Similar changes of acinar to endocrine cell neoplasms have
also been observed in EL-1-Tag mice which develop significant
incidence of islet cell tumors. The present study suggests that acinar
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Neurogenin 3 in the pancreatic progenitor cells is often considered as
the master transcriptional factor required for the determination of the
pancreatic endocrine destiny [29–31]. All pancreatic endocrine cells
derive from neurogenin 3-positive cells, while deletion of neurogenin 3
eliminates the differentiation of pancreatic endocrine cells [32].
However, lineage tracing studies have revealed that neurogenin 3-
expressing cells can eventually adopt acinar or ductal fates if its
expression level is not sufficient to secure the islet destiny [33–35]. This
observation is in line with our finding of acinar adenocarcinoma in
Neuroge3-Tsc1−/−mice. Whether the competence of neurogenin 3
positive cells to give rise to acinar neoplasm is an intrinsic property of
these progenitors or depends on the change of the pancreatic
microenvironment in the Neuroge3-Tsc1−/−mice requires further
investigation. Further experiments using other transcriptional factors
such as Pdx-1 to drive the deletion of TSC1 or deletion of Pten are
important to clarify whether the deletion of TSC1 gene driven by
neurogenin3 specifically causes pancreatic acinar carcinoma. Since
absence of Pten in pancreas driven by Pdx-1 has been reported to cause
progressive premalignant lesions mainly in the ductal linage [36], it is
unlikely that TSC1 gene deletion driven by Pten-cre will cause the
development of acinar carcinoma.Whether deletion of TSC1 by p48 or
elastase-cre will lead to the development of pancreatic acinar carcinoma
is of interest.
The molecular events driving the development of pancreatic
carcinoma remains poorly understood. Our study provides the first
evidence demonstrating that activation of mTOR signaling in
pancreas is sufficient to induce the development of pancreatic acinar
carcinoma. This finding is consistent with previous studies showing
that chronic activation of mTOR complex 1 is sufficient to cause
hepatocellular carcinoma in mice. Evidences from the studies on
hepatocellular carcinoma indicate that activation of mTOR may
promote the carcinogenesis by a mechanism involving unresolved
endoplasmic reticulum stress and defects in autophagy [37]. Previous
study also demonstrates that inhibition of mTOR signaling by
rapamycin significantly attenuates the growth of AR42J cells, a rat
pancreatic exocrine tumor cell line. In addition, several evidences have
suggested the relevance of mTOR signaling with human pancreatic
acinar cell carcinoma. [1] Acinar cell carcinoma of the pancreas has
been described in a patient with Peutz-Jeghers syndrome and biallelic
inactivation of LKB1 allele demonstrated in this tumor, suggesting a
causative role of LKB1 in the development of pancreatic acinar cell
carcinoma [38,39]. Of note, LKB1 activates AMPK which then
inhibits mTOR signaling. [2] Treatment with mTOR inhibitor
results in partial remission of the tumor [39]. [3] Somatic mutations
of EIF4G2, the downstream effector of mTOR, have been identified
in human pancreatic neoplasms with acinar differentiation [40]. As an
important nutrient-sensitive protein kinase, mTOR may thus
represent a key molecular link between pancreatic cancer risk and
environmental factors such as high fat diet.
In conclusion, this study provides the first evidence that activation
of mTOR signaling in the pancreatic progenitor cells may trigger the
development of acinar carcinoma. These results imply that mTOR
signaling in the pancreas may serve as a potential target for treatment
of pancreatic acinar carcinoma.
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